Last reviewed · How we verify

Tapentadol Prolonged Release — Competitive Intelligence Brief

Tapentadol Prolonged Release (Tapentadol Prolonged Release) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mu-opioid receptor agonist and noradrenaline reuptake inhibitor. Area: Pain Management.

marketed Mu-opioid receptor agonist and noradrenaline reuptake inhibitor Mu-opioid receptor; noradrenaline transporter (NET) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Tapentadol Prolonged Release (Tapentadol Prolonged Release) — Grünenthal GmbH. Tapentadol is a mu-opioid receptor agonist and noradrenaline reuptake inhibitor that provides analgesia through dual mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tapentadol Prolonged Release TARGET Tapentadol Prolonged Release Grünenthal GmbH marketed Mu-opioid receptor agonist and noradrenaline reuptake inhibitor Mu-opioid receptor; noradrenaline transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mu-opioid receptor agonist and noradrenaline reuptake inhibitor class)

  1. Grünenthal GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tapentadol Prolonged Release — Competitive Intelligence Brief. https://druglandscape.com/ci/tapentadol-prolonged-release. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: